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Introduction {#ehf212754-sec-0004}
============

Heart failure with preserved ejection fraction (HFpEF) has accounted for approximately 50% of heart failure (HF) hospitalizations worldwide, and it was also related to an increased risk of mortality.[^1^](#ehf212754-bib-0001){ref-type="ref"}, [^2^](#ehf212754-bib-0002){ref-type="ref"}, [^3^](#ehf212754-bib-0003){ref-type="ref"}, [^4^](#ehf212754-bib-0004){ref-type="ref"} Nevertheless, the accurate diagnosis of HFpEF was even more challenged in the absence of congestive symptoms and signs.[^5^](#ehf212754-bib-0005){ref-type="ref"}, [^6^](#ehf212754-bib-0006){ref-type="ref"} Invasive hemodynamic measures with or without exercise tests would be helpful to identify elevated left ventricular end‐diastolic pressure in patients with unexplained dyspnoea.[^7^](#ehf212754-bib-0007){ref-type="ref"}, [^8^](#ehf212754-bib-0008){ref-type="ref"} However, the routine application of right heart catheterization for the diagnosis of HFpEF seems to be unpractical.[^8^](#ehf212754-bib-0008){ref-type="ref"}, [^9^](#ehf212754-bib-0009){ref-type="ref"} Recently, Reddy et al. developed H~2~FPEF score to discriminate HFpEF from non‐cardiac causes of dyspnoea, while HFpEF was recognized by elevated pulmonary arterial wedge pressure (PAWP) at rest or during exercise.[^7^](#ehf212754-bib-0007){ref-type="ref"} H~2~FPEF score was composed of clinical characteristics and echocardiography, including age, body mass index, hypertension, atrial fibrillation, pulmonary hypertension, and elevated left ventricular filling pressure, to propose the likelihood of HFpEF.

But an elevated PAWP is not specific exclusively for HFpEF, patients with chronic obstructive pulmonary disease (COPD) may also have presented with left ventricular diastolic dysfunction and raised left ventricular end‐diastolic pressure in the previous studies.[^10^](#ehf212754-bib-0010){ref-type="ref"}, [^11^](#ehf212754-bib-0011){ref-type="ref"}, [^12^](#ehf212754-bib-0012){ref-type="ref"} COPD is a common cause of dyspnoea, and it is highly prevalent in patients with HFpEF.[^13^](#ehf212754-bib-0013){ref-type="ref"}, [^14^](#ehf212754-bib-0014){ref-type="ref"} Because Reddy et al. have excluded subjects with significant lung diseases, we wondered whether H~2~FPEF score can be generalized to the patients firstly presented with dyspnoea on exertion. In this study, we therefore investigated the associations of H~2~FPEF score with clinical characteristics, echocardiographic indices, and pulmonary function in an Asian population. We further evaluated the prognostic impacts of H~2~FPEF score in dyspnoeic subjects.

Methods {#ehf212754-sec-0005}
=======

Study population {#ehf212754-sec-0006}
----------------

The study population was drawn from an administrative registry to INvestigate Heart And Lung intERaction (INHALER registry). The registry was composed of 8963 ambulatory outpatients, who complained of exertional dyspnoea from August 2005 to December 2012. All of them have received both pulmonary function tests and echocardiographic studies. Patients with left ventricular ejection fraction of \<50%, significant valvular heart disease, severe hepatic disease, haematopoietic diseases, or active malignancy, were excluded from this analysis. (Figure [S1](#ehf212754-supitem-0001){ref-type="supplementary-material"}) The investigation was conformed to the principles outlined in the Declaration of Helsinki. The institutional review committee of Taipei Veterans General Hospital approved the registry data to be used for study purposes.

Data of demographic characteristics, electrocardiogram, laboratory data, echocardiography, and medications were prospectively inputted in a web‐based medical recording system. Estimated glomerular filtration (eGFR) rate was calculated using the Chinese Modification of Diet in Renal Disease equation.[^15^](#ehf212754-bib-0015){ref-type="ref"} Body mass index was universally expressed in kg/m^2^.

Left ventricular end‐diastolic dimension, end‐systolic dimension, left ventricular end‐diastolic volume, left ventricular mass (LVM), left atrial (LA) dimension, and left ventricular ejection fraction were obtained.[^16^](#ehf212754-bib-0016){ref-type="ref"} E/A ratio represented the ratio of left ventricular early (E) to late (A) filling flow velocity. E/e\' was the ratio of early ventricular filling flow velocity (E) to the septal mitral annulus tissue velocity (e\'). Pulmonary artery systolic pressure (PASP) was also estimated. Left ventricular diastolic dysfunction was defined if ≥3 of the following measures were fitted[^1^](#ehf212754-bib-0001){ref-type="ref"}: septal e\' velocity \< 7 cm/s,[^2^](#ehf212754-bib-0002){ref-type="ref"} septal E/e\' ratio \> 15,[^3^](#ehf212754-bib-0003){ref-type="ref"} PASP \> 35 mmHg, and[^4^](#ehf212754-bib-0004){ref-type="ref"} LA dimension \>40 mm.

Pulmonary function test was performed standardly by body plethysmograph (MasterScreen Body Plethysmograph, Erich Jaeger GmbH, Würzburg, Germany) and spirometry (CPFS/D USB, Medical Graphics, St Paul, Minnesota, USA). According to the statement of American Thoracic Society standards, residual volume, total lung capacity (TLC), forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) were presented as the percentage of their predicted values. The obstructive and restrictive ventilation defects were defined as the ratio of FEV1 to FVC below 70% and the predicted %TLC below 80%, respectively.[^17^](#ehf212754-bib-0017){ref-type="ref"} COPD was diagnosed by the clinical physicians and a pre‐bronchodilator FEV1/FVC ratio of \<0.7. Subjects who were diagnosed as asthma or had received monotherapy with inhaled corticosteroid were excluded.

H~2~FPEF score was determined by six variables, including, 3 points for atrial fibrillation, 2 points for obesity, and 1 point for each of the follows: two or more hypertensive drugs, pulmonary hypertension (PASP \> 35 mmHg), elder (age \> 60), and elevated filling pressures (E/e\' ratio \> 9).[^7^](#ehf212754-bib-0007){ref-type="ref"}

Follow‐up {#ehf212754-sec-0007}
---------

We would identify the causes and dates of death of the study population by linking to the National Death Registry.[^18^](#ehf212754-bib-0018){ref-type="ref"} The study population was followed for up to 60 months.

Statistical analysis {#ehf212754-sec-0008}
--------------------

Continuous and categorical variables were presented as mean ± standard deviation and the absolute numbers and relative frequencies, respectively. The differences between groups were compared by Chi‐square tests and Student\'s *t*‐test as appropriate. Cox proportional hazards models were used to evaluate the independence of H~2~FPEF in the prediction of mortality with adjustments for sex, haemoglobin, eGFR, and comorbidities. All the statistics were performed using [spss]{.smallcaps} v.22.0 software (SPSS, Inc., Chicago, IL, USA). All the tests performed were two‐sided and a *P* value of \<0.05 was considered statistically significant.

Results {#ehf212754-sec-0009}
=======

The study population was composed of 5849 patients (age 65.6 ± 16.4 years, 54% men, and mean H~2~FPEF score 2.04 ± 1.50), presented with dyspnoea on exertion to the outpatient clinics. The baseline characteristics were presented in *Table* [*1*](#ehf212754-tbl-0001){ref-type="table"}, stratified by H~2~FPEF score. In short, patients with high H~2~FPEF score (*n* = 160, 2.7%) were older, more likely to be men, and have COPD, diabetes, hypertension, and atrial fibrillation. Haemoglobin and eGFR decreased along with the order of low, intermediate, and high H~2~FPEF score. In contrast, LVM, septal E/e\', LA dimension, left ventricular internal diameter in diastole, left ventricular internal dimension in systole, and PASP increased along with the increase of H~2~FPEF score. Regarding the pulmonary function indices, predicted %TLC, predicted %FEV1, predicted %FVC, and FEV1/FVC ratio declined and residual volume/TLC ratio increased in subjects with higher H~2~FPEF score.

###### 

Baseline characteristics of the study population

  Characteristic                            HF2PEF score 0 \~1 (*n* = 2453)   HF2PEF score 2--5 (*n* = 3236)   HF2PEF score 6--9 (*n* = 160)   *P* value
  ----------------------------------------- --------------------------------- -------------------------------- ------------------------------- -----------
  Age (years)                               55.0 ± 16.4                       72.7 ± 11.4                      79.7 ± 7.05                     \<0.001
  Male gender, *n* (%)                      1,189 (48.6)                      1869 (58.1)                      109 (68.1)                      \<0.001
  Body mass index                           23.4 ± 3.3                        26.3 ± 14.0                      32.6 ± 26.9                     \<0.001
  Co‐morbidity, *n* (%)                                                                                                                        
  COPD                                      148 (6.0)                         456 (14.1)                       41 (25.6)                       \<0.001
  Diabetes mellitus                         285 (11.6)                        835 (25.9)                       66 (41.3)                       \<0.001
  Coronary artery disease                   881 (35.9)                        1,433 (44.3)                     68 (42.5)                       \<0.001
  Hypertension                              618 (25.2)                        1840 (56.9)                      129 (80.6)                      \<0.001
  Atrial fibrillation                       0 (0)                             198 (6.1)                        138 (86.3)                      \<0.001
  Echocardiography                                                                                                                             
  LV diastolic dysfunction, *n* (%)         1 (0.0)                           255 (7.8)                        47 (29.3)                       \<0.001
  LVEF (%)                                  71.5 ± 8.7                        71.5 ± 9.5                       69.9 ± 9.2                      0.097
  LVM (g)                                   159.3 ± 67.6                      191.3 ± 70.1                     203.3 ± 64.7                    \<0.001
  Septal E/e\'                              8.5 ± 3.0                         13.6 ± 5.6                       15.6 ± 6.1                      \<0.001
  Mitral E/A ratio                          1.10 ± 0.48                       0.89 ± 0.43                      1.08 ± 0.69                     \<0.001
  LA diameter (mm)                          35.5 ± 7.3                        41.2 ± 8.7                       49.2 ± 9.6                      \<0.001
  LVIDd (mm)                                47.1 ± 12.6                       48.3 ± 7.5                       48.5 ± 7.1                      \<0.001
  LVIDs (mm)                                27.5 ± 5.6                        28.3 ± 6.5                       29.0 ± 6.0                      \<0.001
  PASP (mmHg)                               28.6 ± 11.9                       39.4 ± 16.4                      49.9 ± 16.0                     \<0.001
  Hemogram and Biochemistry, on admission                                                                                                      
  Haemoglobin (g/dL)                        12.7 ± 2.1                        12.0 ± 2.1                       11.7 ± 2.0                      \<0.001
  eGFR (mL/min/1.73m^2^)                    87.1 ± 28.5                       71.4 ± 30.8                      57.4 ± 29.0                     \<0.001
  Sodium (mEq/L)                            139.2 ± 3.3                       139.0 ± 3.6                      139.2 ± 4.0                     0.138
  Potassium (mEq/L)                         4.08 ± 0.68                       4.12 ± 0.56                      4.07 ± 0.64                     0.788
  Pulmonary function test                                                                                                                      
  Predicted RV%                             106.9 ± 33.6                      104.8 ± 33.9                     102.9 ± 30.7                    0.109
  Predicted TLC%                            92.5 ± 17.2                       88.9 ± 22.4                      83.6 ± 16.0                     \<0.001
  Predicted VC%                             85.5 ± 19.7                       78.1 ± 20.4                      69.6 ± 20.5                     \<0.001
  RV/TLC ratio, %                           38.5 ± 10.9                       46.2 ± 11.1                      50.9 ± 11.6                     \<0.001
  FEF 25% to 75%, (L/s)                     2.35 ± 1.20                       1.50 ± 0.90                      1.21 ± 0.79                     \<0.001
  Predicted FEV1%                           86.7 ± 22.0                       78.6 ± 24.2                      70.5 ± 24.3                     \<0.001
  Predicted FVC%                            85.2 ± 20.0                       75.8 ± 21.6                      66.8 ± 21.1                     \<0.001
  FEV1/FVC ratio, %                         80.1 ± 10.8                       75.7 ± 12.0                      73.8 ± 13.2                     \<0.001

COPD, chronic obstructive pulmonary disease; E/A ratio, ratio of the early (E) to late (A) ventricular filling velocities; E/E\', ratio of early ventricular filling velocity (E) to early diastolic tissue velocity mitral annulus; eGFR, estimated glomerular filtration; FEF 25% to 75%, forced expiratory flow at 25%--75% of the pulmonary volume; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; LA, left atrium; LV, left ventricle; LVEDD, left ventricular end‐diastolic dimension; LVEDV, left ventricular end‐diastolic volume; LVEF, left ventricular ejection fraction; LV mass, left ventricular mass; PASP, pulmonary artery systolic pressure; RV, residual volume; TLC, total lung capacity; VC, vital capacity

Pulmonary function and H~2~FPEF score {#ehf212754-sec-0010}
-------------------------------------

On one hand, the prevalence of obstructive ventilation defect[^19^](#ehf212754-bib-0019){ref-type="ref"} was 12.8%, 26%, and 36.9% in subjects with low, intermediate, and high H~2~FPEF score. (*Figure* [*1*](#ehf212754-fig-0001){ref-type="fig"}) On the other hand, restrictive ventilation defects were presented in 17.7%, 26.4%, and 38.1% of the patients with low, intermediate, and high H~2~FPEF score, respectively. (*Figure* [*1*](#ehf212754-fig-0001){ref-type="fig"}) H~2~FPEF score was positively related to the prevalence of pulmonary function abnormalities.

![The distributions of the pulmonary function abnormalities, stratified by H~2~FPEF score of 0--1, 2--5, and 6--9. The obstructive and restrictive ventilation defects were defined as forced expiratory volume in 1 s/forced vital capacity of \<0.7 and the predicted %TLC of \<80%, respectively.](EHF2-7-1872-g001){#ehf212754-fig-0001}

Among the subpopulation without COPD, 44.2% of them had low H~2~FPEF score of 0 or 1. (*Figure* [*2*](#ehf212754-fig-0002){ref-type="fig"}) In contrast, only 22.9% of the subpopulation with COPD had low H~2~FPEF score. H~2~FPEF score was significantly higher in subjects with COPD than those without (2.57 ± 1.44 vs, 1.91 ± 1.45, *P* \< 0.001). (*Figure* [*2*](#ehf212754-fig-0002){ref-type="fig"}).

![The distributions of H~2~FPEF score in subjects with or without chronic obstructive pulmonary disease (COPD).](EHF2-7-1872-g002){#ehf212754-fig-0002}

Prognostic impacts of H~2~FPEF score {#ehf212754-sec-0011}
------------------------------------

During a mean follow‐up duration of 30.0 ± 20.5 months, there were 897 deaths and 230 cardiovascular mortalities. The long‐term survival probabilities were 88.5%, 82.3%, and 75.0% of patients with low, intermediate, and high H~2~FPEF score, respectively. The Kaplan--Meier survival curve analysis demonstrated significantly survival discrepancies among the three groups. (*Figure* [*3*](#ehf212754-fig-0003){ref-type="fig"}).

![The Kaplan--Meier survival curve analysis of the study population, stratified by H~2~FPEF score of 0--1, 2--5, and 6--9.](EHF2-7-1872-g003){#ehf212754-fig-0003}

Among the study population, H~2~FPEF score, male gender, LVM, haemoglobin, eGFR, the presence of COPD, and diabetes were all related to long‐term survival in univariate Cox regression analysis. (*Table* [*2*](#ehf212754-tbl-0002){ref-type="table"}) The multivariate Cox regression analysis suggested H~2~FPEF score was associated with mortality \[Hazard ratios and 95% confidence interval: 1.063 (1.010--1.118)\], independently of gender, haemoglobin, LVM, eGFR, COPD, and diabetes. (*Table* [*2*](#ehf212754-tbl-0002){ref-type="table"}).

###### 

Predictors of 5‐year mortality identified by univariable and multivariable Cox regression analysis

  Characteristic            Univariable            Multivariable                          
  ------------------------- ---------------------- --------------- ---------------------- ---------
  H2FPEF score              1.126 (1.178--1.276)   \<0.001         1.063 (1.010--1.118)   0.019
  Sex (male)                1.527 (1.332--1.752)   \<0.001         1.341 (1.142--1.575)   \<0.001
  Presence of COPD          1.502 (1.248--1.807)   \<0.001         1.343 (1.083--1.666)   0.007
  Presence of diabetes      1.401 (1.204--1.629)   \<0.001         1.017 (1.142--1.575)   0.849
  LVM (g)                   1.003 (1.002--1.004)   \<0.001         0.999 (0.998--1.001)   0.120
  Haemoglobin (g/dL)        0.803 (0.778--0.829)   \<0.001         0.846 (0.817--0.877)   \<0.001
  eGFR (mL/min/1.73 m^2^)   0.988 (0.986--0.990)   \<0.001         0.994 (0.991--0.996)   \<0.001

CI, confidence interval; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; LVM, left ventricular mass.

Discussion {#ehf212754-sec-0012}
==========

While H~2~FPEF score may have provided the probability of HFpEF in dyspnoeic patients,[^7^](#ehf212754-bib-0007){ref-type="ref"} ventilatory abnormalities also prevail in subjects with high H~2~FPEF score. The present study demonstrated patients with high H~2~FPEF score were more likely to have either obstructive or restrictive ventilation defects. The results may support to survey pulmonary function in dyspnoeic patients with high H~2~FPEF score, in addition to the evaluation of HFpEF. Furthermore, the study may firstly show the long‐term prognostic values of H~2~FPEF score in dyspnoeic subjects, regardless of patients with or without COPD.

The associations between heart failure with preserved ejection fraction and abnormalities of ventilation function {#ehf212754-sec-0013}
-----------------------------------------------------------------------------------------------------------------

While lung function abnormalities were prevalent in patients with HFpEF,[^20^](#ehf212754-bib-0020){ref-type="ref"} Obokata and Ries et al. have further demonstrated the reduced ventilation reserve and significant restrictive change along with the increase of PAWP and pulmonary artery pressures in patients undergoing cardiac cathe1terization.[^21^](#ehf212754-bib-0021){ref-type="ref"}, [^22^](#ehf212754-bib-0022){ref-type="ref"} In contrast, the obstructive change of ventilation related to submucosal oedema in decompensated HF was also anticipated.[^23^](#ehf212754-bib-0023){ref-type="ref"}

In the present study, subjects with high H2FPEF score were more likely to have restrictive and/or obstructive ventilatory defects. The predicted TLC, FEF25--75 and FEV1/FVC decreased along with the increase of H2FPEF score. Given H2FPEF score may indicate the probability and severity of HFpEF, the study results would support the ventilatory abnormalities prevails in patients with HFpEF.

The identification and treatment of concomitant heart failure and chronic obstructive pulmonary disease {#ehf212754-sec-0014}
-------------------------------------------------------------------------------------------------------

Chronic obstructive pulmonary disease is prevalent in patients with HFpEF, and it is associated with adverse clinical outcomes and poor quality of life.[^24^](#ehf212754-bib-0024){ref-type="ref"}, [^25^](#ehf212754-bib-0025){ref-type="ref"} The efficacy and safety of cardioactive inhaled pulmonary drugs is controversial in treating HF patients with or without lung comorbidities.[^5^](#ehf212754-bib-0005){ref-type="ref"}, [^26^](#ehf212754-bib-0026){ref-type="ref"}, [^27^](#ehf212754-bib-0027){ref-type="ref"}, [^28^](#ehf212754-bib-0028){ref-type="ref"} Therefore, it is critical to identify the subjects with concomitant HF and COPD. In our study, up to 14.1% and 25.6% of the patients with intermediate and high H2FPEF score had documented COPD by spirometry, respectively. The comprehensive echocardiography and pulmonary function tests would be helpful to demonstrate cardiac or pulmonary abnormalities objectively, especially when it was challenging to differentiate a cardiac disease from pulmonary disease and vice versa by clinical findings.[^29^](#ehf212754-bib-0029){ref-type="ref"}

About 70.7% and 53.3% of patients with and without COPD had a H2FPEF score of 2 to 5, respectively, indicating that the majority of the study population warrants further survey for HFpEF. However, only 2.3% to 6.4% of the dyspnoeic patients, regardless of COPD had high H2FPEF score. While HFpEF was highly suspected, subjects should therefore undergo right heart catheterization for confirmation.

Prognostics impacts of H~2~FPEF score {#ehf212754-sec-0015}
-------------------------------------

The long‐term outcomes of HFpEF remain dismal, while the mortality rate and HF hospitalization of HFpEF are as high as those with reduced left ventricular ejection fraction.[^30^](#ehf212754-bib-0030){ref-type="ref"}, [^31^](#ehf212754-bib-0031){ref-type="ref"} Although H~2~FPEF score was designed to evaluate the probability of HFpEF rather than to predict the clinical outcomes, its component variables, including PASP, body mass index, and atrial fibrillation have been related to survival in HFpEF.[^32^](#ehf212754-bib-0032){ref-type="ref"}, [^33^](#ehf212754-bib-0033){ref-type="ref"}, [^34^](#ehf212754-bib-0034){ref-type="ref"} The prognostic associations with H2FPEF score could have been anticipated. However, in the present study, we might firstly demonstrate H~2~FPEF score was correlated with increased risks of long‐term mortality in dyspnoeic patients, independent of morbidities, LVM, haemoglobin, and eGFR. The findings may support that H~2~FPEF score could not only identify a specific population with increased risk of HFpEF but also adverse clinical outcomes, regardless of diabetes, pulmonary disorders, anaemia, chronic kidney disease, or left ventricular hypertrophy. Given the baseline characteristics of HFpEF were heterogeneous, the study results also suggested the clinical application of H~2~FPEF score for risk stratifications and tailored therapies.

Study limitations {#ehf212754-sec-0016}
-----------------

There were several study limitations in this work. First, we did not conduct the right heart catheterization for the diagnosis of HFpEF in all participants, because this was not a validation study of H~2~FPEF score. In addition, we were not able to diagnose HFpEF precisely while the data of left atrial volume and brain natriuretic peptide was lack. But we did show the prevalence of HFpEF increased along with the increased H2FPEF score. In this study, we did further extend its clinical associations with pulmonary functions and long‐term survival. Second, selection bias could not be excluded, giving that this was an observational study. But we have adjusted for all the available confounders to evaluate the independent prognostic values of H~2~FPEF. Third, the diagnosis of HFpEF is very difficult in patients with concomitant COPD, while both diseases may share similar risk factors, such as old age and obesity. And COPD could consequently cause atrial fibrillation, pulmonary hypertension, and abnormal E/e\' ratio. Fourth, data of HF hospitalization were not fully available in this study. Further studies are needed to address the correlations of H~2~FPEF score with morbidity.

Conclusion {#ehf212754-sec-0017}
==========

While H~2~FPEF score has been validated to evaluate the probability of HFpEF, the present study further extended its correlations with pulmonary functions. Although it could be difficult to identify HFpEF in patients with concomitant COPD, subjects with high H~2~FPEF score would more likely to have either obstructive or restrictive ventilatory defects. In addition, H~2~FPEF score was independently associated with long‐term survival in the study population, who presented with exertional dyspnoea. Because the underline aetiologies of HFpEF were heterogeneous, this study may also have proposed the prognostic values of H2FPEF score in HFpEF. Further studies may be needed to survey the clinical application of H2FPEF score for the diagnosis of HFpEF, and a multidisciplinary approach is indicated to manage patients with concomitant COPD.
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